Mirati’s Pivotal NSCLC Disappointment For Sitravatinib Combo ‘Unsurprising’
Krazati Remains Focus
Executive Summary
The US firm’s kinase inhibitor fell short of overall survival expectations in combination with a PD-1 inhibitor in an advanced lung cancer trial, but upcoming milestones for Krazati may be more of a concern.